IsoPlexis eBook - 4

Application Note

The Power of PSI
in Evaluating CAR-T Therapy
Additional Content

By MaryAnn Labant
IsoPlexis' Polyfunctional Strength Index (PSI) demonstrates
utility and performance in evaluating preclinical, clinical
and manufacturing data in CAR-T therapies.


himeric Antigen Receptor (CAR) T cell immunotherapy holds
enormous potential for the treatment of cancer. The goal of
cell therapy is to not only achieve tumor reduction but also
to activate an anti-tumor immune response. But many challenges
remain, despite the remarkable success of CAR-T immunotherapy
for some patients. Unfortunately, it remains unclear how to optimize
the therapy.
Re-engineered T cells are living products; this makes their behavior
difficult to characterize and predict. Unlike a small molecule or antibody that always has the same structure, each time an autologous
cell therapy is developed the starting material comes from a different
patient. This makes it virtually impossible to reproducibly develop
an identical "drug". Even if therapy began with similar cells, the result
would most likely have different potencies and activities.



This is because in vivo cellular expansion cannot be predicted
uniformly across a group of patients-it depends on multiple
factors including the tumor microenvironment, target antigen
expression intensity, distribution and organ site. Additionally, lifethreatening immunotoxicity sometimes results once CAR-T cells are
re-infused into the patient, such as cytokine release syndrome and
neurologic toxicity.
Today's standard methods to evaluate quality and potency are inadequate to select products that provide better patient outcomes. Quality assays are mainly descriptive with some objective parameters like
cytokine production, cytotoxicity, and proliferation.
Researchers and clinicians urgently need new approaches to understand the functional profile of cell therapy products to accelerate
discovery and development, to achieve manufacturing consistency,
and to predict which patients will derive the most value from these
drugs while minimizing side-effects. Population level studies cannot
provide the necessary insight into immune response heterogeneity
at the single-cell level.

See how IsoPlexis advances cell
immunotherapy by correlating specific
single-cell cytokine levels to CRS and
neurotoxicity in our application
highlight: Single-Cell Polyfunctional
Inflammation Biomarkers for
Immune Related Adverse Events.

Download It Here

IsoPlexis eBook

Table of Contents for the Digital Edition of IsoPlexis eBook

IsoPlexis eBook - 1
IsoPlexis eBook - 2
IsoPlexis eBook - Contents
IsoPlexis eBook - 4
IsoPlexis eBook - 5
IsoPlexis eBook - 6
IsoPlexis eBook - 7
IsoPlexis eBook - 8
IsoPlexis eBook - 9
IsoPlexis eBook - 10
IsoPlexis eBook - 11
IsoPlexis eBook - 12
IsoPlexis eBook - 13
IsoPlexis eBook - 14
IsoPlexis eBook - 15